CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
43.30
-1.43 (-3.20%)
At close: Dec 5, 2025, 4:00 PM EST
43.67
+0.37 (0.85%)
After-hours: Dec 5, 2025, 6:24 PM EST
CG Oncology Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for CG Oncology stock have an average target of 67.64, with a low estimate of 47 and a high estimate of 90. The average target predicts an increase of 56.21% from the current stock price of 43.30.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 8 | 7 |
| Buy | 4 | 5 | 6 | 6 | 6 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 12 | 13 | 14 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $62 | Strong Buy | Initiates | $62 | +43.19% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $53 → $61 | Buy | Maintains | $53 → $61 | +40.88% | Nov 17, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $90 | Strong Buy | Initiates | $90 | +107.85% | Oct 8, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $41 → $47 | Buy | Maintains | $41 → $47 | +8.55% | Sep 26, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $56 → $79 | Buy | Maintains | $56 → $79 | +82.45% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
1.89M
from 1.14M
Increased by 66.11%
Revenue Next Year
57.13M
from 1.89M
Increased by 2,919.34%
EPS This Year
-2.20
from -1.41
EPS Next Year
-2.77
from -2.20
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.4M | 268.6M | ||||
| Avg | 1.9M | 57.1M | ||||
| Low | 1.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 112.0% | 14,094.0% | ||||
| Avg | 66.1% | 2,919.3% | ||||
| Low | 46.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.01 | -1.77 | ||||
| Avg | -2.20 | -2.77 | ||||
| Low | -2.21 | -3.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.